- Day One Announces Sale of Priority Review Voucher for $108 Million
- Day One Reports First Quarter 2024 Financial Results and Corporate Progress
- Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
- Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
- Day One Announces Two New Appointments to Board of Directors
- Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
- Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference
- Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
- Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
More ▼
Key statistics
On Wednesday, Day One Biopharmaceuticals Inc (DAWN:NSQ) closed at 13.00, 34.44% above the 52 week low of 9.67 set on Oct 20, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.31 |
---|---|
High | 13.24 |
Low | 12.31 |
Bid | 12.11 |
Offer | 13.10 |
Previous close | 13.00 |
Average volume | 987.88k |
---|---|
Shares outstanding | 87.39m |
Free float | 70.16m |
P/E (TTM) | -- |
Market cap | 1.10bn USD |
EPS (TTM) | -2.50 USD |
Data delayed at least 15 minutes, as of Jun 12 2024 21:00 BST.
More ▼